In Preparation for European Partnership, Oculus Innovative Sciences Expects Expanded Label Claim for European Formulation of

In Preparation for European Partnership, Oculus Innovative Sciences Expects
Expanded Label Claim for European Formulation of Dermacyn(TM) Wound Care

Upgraded Class III CE Mark to Include Claim of Potential Local Antimicrobial
Effectiveness in Open Wounds

PETALUMA, Calif., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS) a healthcare company that designs, produces and
markets innovative, safe and effective anti-infective products and medical
devices while also developing multiple drug candidates, today announced that a
pending reclassification of the company's CE Mark for the European formulation
Dermacyn™ Wound Care for the European market is expected by year's end. The
reclassification is under the review of the British Standards Institution
(BSI), which is the world's largest certification body, and the Medicines and
Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
Reclassified as a class III medical device, the newest indication would
include "possible local antimicrobial effect in the wound bed." 

"We are pleased with the expanded label indication as it will help increase
sales for our existing sales partners in Europe and secondly, increases our
chances of licensing our anti-infective drug product to prospective European
partners focused on the surgical suite," said HojiAlimi, Oculus founder and
CEO. "As evidenced by our effective collaborative effortswith partners in the
United States and Mexico, our partnership strategy has facilitated
asustainable rapid sales ramp while minimizing expenses since our partners
underwrite thecosts associated with marketing and sales."

About Oculus Innovative Sciences

Oculus Innovative Sciences is a healthcare company that designs, produces and
markets innovative, safe and effective anti-infective products and medical
devices while also developing multiple drug candidates for various indications
including treatment of acne and surgical suite use. Oculus is pioneering
innovative solutions in multiple markets for the dermatology, surgical, wound
care, and animal healthcare markets, and has commercialized products in the
United States, Europe, India, China, Mexico and select Middle East countries.
The company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. More information can be
found at www.oculusis.com.

Oculus press releases contain information about products, which may or may not
be available in any particular country, and if applicable, may have received
approval or market clearance by a governmental regulatory body for different
indications and restrictions in different countries. Each country has specific
laws, regulations and medical practices governing the communication of medical
or other information about medical products. Nothing herein should be
construed as a solicitation or promotion for any product or for an indication
for any product, which is not authorized by the laws and regulations of the
country where the reader resides.

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "providing," "growing" and"afflicted,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:

         Oculus Innovative Sciences, Inc.
         Dan McFadden
         Director of Public and Investor Relations
         (425) 753-2105
 
Press spacebar to pause and continue. Press esc to stop.